Newsfeeds Archive - Page 3 of 4

3 minute read

News

Lantern Pharma Leverages AI Platform, RADR, To Develop Breakthrough Antibody Drug Conjugates In Collaboration With Bielefeld University

June 8, 9:02 AM

Lantern will leverage its proprietary AI platform, RADR®, to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates. The

LTRN

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For May 18, 2023

By Benzinga Insights

May 18, 11:00 AM

Upgrades According to CIBC, the prior rating for BlackBerry Ltd (NYSE:BB) was changed from Underperformer to Neutral. In…

ABOS

29 minute read

Earnings

Earnings Scheduled For May 9, 2023

By Benzinga Insights

May 9, 6:03 AM

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.

ABNB

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

March 27, 9:06 AM

Gainers Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 33.6% to $0.58 during Monday’s pre-market session. The company’s market cap stands…

ADIL

2 minute read

Lantern Pharma Receives Pre-IND Feedback From The FDA, Clearing A Path For Drug Candidate LP-184’s Phase 1 Clinical Trial In Q2 2023

By Benzinga Newsdesk

January 17, 9:01 AM

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the

LTRN

2 minute read

Lantern Pharma Announces Data Highlighting The Anti-Tumor Potency Of Drug Candidate LP-184 For Glioblastoma At The Society For Neuro-oncology Annual Meeting

By Benzinga Newsdesk

November 22, 9:08 AM

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the

LTRN

13 minute read

Earnings

Earnings Scheduled For November 7, 2022

By Benzinga Insights

November 7, 4:59 AM

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

AAON

1 minute read

Earnings

Earnings Preview: Lantern Pharma

By Benzinga Insights

November 4, 12:28 PM

Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Lantern Pharma will report an earnings per share (EPS) of $-0.54.

LTRN